Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I tend to agree with you. Hopefully they can strike a deal on another HOT application.
Ubmmg,you caught in traffic or voting? Maybe should have checked with I-hub on Nat. T cell killers?
Question is how fast will my posts be deleted?
“The results demonstrate that AXAL can induce changes in the tumor microenvironment that promote NK cell activation, establish cross-talk between dendritic cells (DC cells), NK cells, and can facilitate trafficking of tumor antigen-specific T cells into the tumor core which we believe contribute to the antitumor activity of AXAL,” said Robert G. Petit, Ph.D., Executive Vice President and Chief Scientific Officer of Advaxis.
Axal is already doing this; so what new platform?
I am waiting to see how the midterm election results possibly influence the market on Wednesday, but I may add to my position after Wednesday.
I hear yah on that, but sometimes you have to bite the bullet to keep the wife happy. It was an outdoor concert; and after downing a case of Budweiser, I had a good time.
My wife drug me to an outdoor concert to see what's left of the Thompson Twins opening for Boy George back in August. Actually was a very good concert.
Cyber, sorry to hear about you being under water; and also sorry for the warrant holders. Full disclosure, I am a dumb arse drunk redneck. But for what it's worth here is the perception in my insane world.
I have been invested in ADXS since April of 2009, and twice I have been down 90% on my investment and have seen it bounce back to positive territory. Currently I am down 95% on my investment. Personally I would prefer to ride it to bankruptcy rather than sell now; just for the chance that it will bounce back again.
My probable belief is that DOC probably bucked BP partner with HOT and he is now gone. DOC would have probably only diluted above $5 in my opinion. No reason for HOT to be sitting on the sidelines waiting for NEO for two years. So I feel that the board is on probably possibly on the BP partner team.
So best case another BP steps up and invests in HOT or Axal; otherwise we are already probably possibly sold for peanuts.
The possible X-factor in my opinion is how Axal will possibly perform in the locally advanced stage versus metastatic?
1) Anal trial with Brown U. may provide possible insight, although small sample size.
2)Second dose escalation of CIN 2/3 trial and mysterious patent application (CatDog remembers?) may provide insight.
3) Canine Osteosarcoma trial results may provide insight.
So bottom line is that until AIM2CERV results are un-blinded, we really do not know how AXAL will perform in the locally advanced setting versus metastatic?
Wild card may possibly be Merck with prostate?
All above scenarios are very speculative.
Just wondering if AIM2CERV will possibly yield very good results? The thing I am wondering is the possible correlation to the Brown U. Study based on "HPV-associated locally advanced cancer" versus metastatic?
Seems like cervical was a possible candidate for NEO; so unsure if we will see any similar pattern possibly with AIM2CERV versus the Brown U. Study? Time will tell, just hope we get some idea soon on possible AIM2CERV results.
Brown University Oncology Group
Advaxis has collaborated with Brown University Oncology Group on a Phase 1/2 clinical study assessing the safety and efficacy of axalimogene filolisbac administered with concurrent standard chemotherapy and radiation treatment in HPV-associated locally advanced anal cancer. Preliminary data show treatment with axalimogene filolisbac indicated a clinical complete response and no recurrence in all 10 patients who completed the treatment regimen.
AIM2CERV is a global phase 3 study evaluating a novel immunotherapy for women living with high-risk, locally advanced cervical cancer.
I hope we get the tax credit again, but I think there may possibly be a lifetime limit of 15 million? So may be a lesser amount possibly this year if you add up the amounts since 2013; but I do not know for sure?
My apologies, I was looking at last year's article on the investors relation page. The date at the top was current, but the PR is dated November 1st, 2017. So not sure if we will get this tax credit again?
Blue you predicted this back in September. You're my boy!
PS we are too Old School for IHub PC
Advaxis to receive approximately 4.5 million in tax credits?
Hat's off to Australia. Unfortunately the rest of the World may not be so fortunate, and many young males are probably not being vaccinated.
https://deainfo.nci.nih.gov/advisory/pcp/annualReports/HPV/Part4.htm
From my limited knowledge standpoint I am guessing that they probably did not include this biomarker as a requirement for AIM2CERV? Some of the Exclusion criteria possibly are 1) has FIGO Stage IVB. 2) histologies other than squamous cell, adenocarcinoma or adenosquamous carcinoma of the cervix.
I hear you brother, I came to age at the same time. Just wish I knew the dangers of clam diving, damn sharks.
If you ever end up in the Gulf of Mexico swimming behind a shrimp boat at night, probably will only happen once.
Full disclosure: I am a drunk insane redneck. Even such a jack arse like me may have this pegged, research it if you need to?
1) Probable high correlation between canine studies and humans.
2) When cancer metastasizes it is more likely probably to take on your own personal DNA mutations (hence NEO).
3) Our base vaccines will probably work best with early stage localized cancer. Remember the CIN 2/3 patent application back in the day?
4) Others may come up with super proteins, peptides, RNA, yada yada;
but we have the potential to be the delivery vehicle of choice.
5) Platform has potential for infectious disease, childhood vaccination against allergies, disease or flu vaccine on short notice, animal disease, etc.
Hov, any idea how this may possibly compare to this study?
https://www.theguardian.com/society/2018/jun/02/immunotherapy-could-stop-prostate-cancer-spreading-trial-shows
Thank you for the information. I always enjoyed reading Terry's posts and conversing with him over the years. May he RIP.
I have no idea, but the pediatric priority review vouchers have sold for several million dollars in the past, so maybe a possibility?
https://en.wikipedia.org/wiki/Priority_review
Excerpt:
In 2015, a voucher for a pediatric cancer drug developed by United Therapeutics sold for $350 million. At this cost, the voucher would be expected to offset the substantial investment and risk required for discovery and development of a new treatment for a neglected disease. If the time saved from gaining a priority review were much shorter, however, the value of the voucher will be significantly less.
I always speculated that someone would probably pursue the pediatric priority review voucher, which I believe can be sold?
https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM423325.pdf
If the company could pay as much attention to detail as this MB; we would all probably be rich by now. Personally, I hope some other BP steps in and gives the high hard one to the other tight wad (you know who?).
Personally I would not read too much into this, probably a typo. Past history has also shown likely poor proof reading errors.
Seems like HOT for cervical would possibly re-open the rights to the entire world? Hence the main issue here, are you going to someday get possibly replaced by the new and improved versions? Advancing science can sometimes maybe be a double edged sword.
Dodgeball? White Goodman?
Not sure, anything is possible???????
Can not verify accuracy, but here is free on-line translation:
And source link free GOOGLE language converter:
https://translate.google.com/
Of the 50 patients evaluated, 19 survived at 12 months, and the overall 12-month survival rate for conversion to axalimogene filolisbac was 38%. In a recent 20 clinical trials conducted by the Gynecologic Oncology Group (GOG), this is the first trial of a 12-month survival rate for advanced cervical cancer greater than 30%, Ph.D., Public Health at the University of Alabama, Birmingham. Master's first treatment for advanced cervical cancer at 12 months, said Charles A. Leath III, MD, and Master of Public Health, Charles A. Leath III. The first author of the study was Warner Hugh, MD, of the University of Alabama. The study was conducted at twelve American cancer centers.
The researchers point out that the overall survival rate of these patients is more than 50% higher than the expected survival rate. "The highest 12-month survival of patients with severe, treated, recurrent cervical cancer to date," Dr. Leath said.
According to Dr. Leath, the results of this study are comparable to those of bevacizumab in gog-227c. The 12-month survival rate in this study was 30%, which directly led the drug regulatory authorities to use this drug as a first-line drug for combination chemotherapy. “This is very important because about half of the patients in the trial have previously received bevacizumab treatment.”
Axalimogene filolisbac contains an attenuated Listeria livelihood that is engineered to secrete HPV16 protein and fused with the hemolysin listeriolysin O truncation fragment. The conjugate target is HPV transformed cells, induces anti-tumor T cell immunity, and blocks the immune-tolerant tumor microenvironment.
Main findings
The finding comes from the Phase II GOG-0265 trial in patients with treated metastatic cervical cancer. More than half of the patients had previously received at least two treatments that exceeded the initial treatment intention. Three doses of axalimogene filolisbac were administered to patients who had only one treatment and were administered once a month.
At the primary endpoint of the play, the 12-month overall survival rate was 38%, exceeding the pre-set benchmark by more than 50%. In the subgroup carrying HPV16, the survival rate was 44%, and in the subgroup carrying HPV18, the survival rate was 41%.
The most common treatment-related adverse events (all grades) were fatigue (52%), cold (52%), anemia (48%), nausea (32%), and fever (30%). The most common grade 3 / 4 event was anemia, with an incidence of 10% in the patients assessed.
"Now we can see a broad prospect through clinical phase II trials, and we now have a treatment that has the potential to treat recurrent cervical cancer," commented Dr. Lia.
Axalimogene filolisbac has also been evaluated in two other HPV-related cancers: head and neck cancer and anal cancer. The US Food and Drug Administration has granted axolimogen filolisbac orphan drug status for these three clinical settings, as well as the Phase 3 clinical trial AIM2CERV Special Trial Program Evaluation (SPA) qualification, and opened a green channel for it.
My question is Why TF was HOT not in trials during 2017? Maybe that is possibly what Dan wanted to do and it got him axed? Makes no sense to me on the delay since it was revealed right after NEO and should not have probably experienced the same delay schedule?
Crazy thought, but do you think HOT will potentially have a bigger market share than NEO? If they can possibly load LM with up to 100, seems odds would be pretty decent to dial in HOT based on all of the information being collected in data bases.
I seem to remember a joint patent we may have I think with a Merck subsidiary for using LM with PD1. Not sure if this may possibly restrict prostate partner options?
50,000 shares
Blue, you're my boy. You're glorious. Classic Old School.
https://video.search.yahoo.com/search/video?fr=yset_chr_syc_hp-s&p=blue+your+my+boy+old+school#id=7&vid=076ec14eda64cc3c461d407a2068d74c&action=view
Sounds good. I am not a big fan of LA these days, but I will make the party if I am in the green.
Mypeke, as I have been saying since the Amgen NEO deal; the issue here is that the technology has advanced beyond the first generation vaccines. Which is a great problem to have in my opinion. I have always felt that DOC hosed us on the NEO deal, and in my opinion revealing HOT after NEO was his undoing as CEO (which probably made some un-named BP mad as hell). Just the ramblings from a drunk redneck, but I think some much more intelligent people than myself may have bought in big last Friday. Hopefully some other BP will make some deals to stoke the fires.
Thanks Dew, good read. I saw a few long term holders sell out yesterday; but I will see this through to the end.
Allegedly this is the number that DOC was estimating according to another poster. I did a ratio of the prostate market for DNDN at a market cap of 5 Billion and extrapolated this out to the percentage of cancers that could potentially be covered by HOT just in the US market. Granted we will probably have to partner up and may only get a small percentage of the sales, but if we have a potential cure the hype alone may drive our potential market cap to this level for a buyout. I am placing my bets on NEO and HOT, but this is still very speculative so there are no guarantees.
I would settle for 10 billion, even that is fire sale bargain in my opinion for the potential of what we have.
View from 10,000 feet is that if it works we may potentially have 50% of market covered. Thoughts after pounding a 12 pack on a hot day.
Link from 2018 American Cancer Society. Interesting to me to look at page 6 in sequence (labeled page 4) and speculate on potential hot opportunities? Was thinking that NSCLC was estimated at potentially 80% of lung cancers?
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf